Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
about
Progressive effects of valsartan compared with amlodipine in prevention of diabetes according to categories of diabetogenic risk in hypertensive patients: the VALUE trialDirect angiotensin II type 2 receptor stimulation ameliorates insulin resistance in type 2 diabetes mice with PPARĪ³ activationAngiotensin II inhibits insulin-stimulated GLUT4 translocation and Akt activation through tyrosine nitration-dependent mechanisms.Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects.Regulation of oxidative stress and cardioprotection in diabetes mellitus.Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study.Angiotensin receptor blocker/diuretic combination preserves insulin responses in obese hypertensives.Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study.Pharmacological and non-pharmacological interventions to influence adipose tissue function.The therapeutic role of RAS blockade in chronic heart failure.Effect of calcium channel blockers on incidence of diabetes: a meta-analysis.Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) studyCognition and Hemodynamics.Maximising antihypertensive effects of angiotensin II receptor blockers with thiazide diuretic combination therapy: focus on irbesartan/hydrochlorothiazideComplications of hypertension and the role of angiotensin receptor blockers in hypertension trials.Strategies for preventing type 2 diabetes: an update for clinicians.The frail renin-angiotensin system.Prevention of diabetes in hypertensive patients: results and implications from the VALUE trialAmlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.Hypertension and the cardiometabolic syndrome in Chile: a review of concepts and consequences for the developing world.Are renin-angiotensin-aldosterone system blockers distinguishable based on cardiovascular and renal outcomes in nephropathy?A guide to the management of blood pressure in the diabetic hypertensive patient.Adiponectin and hypertension.The role of ARBs alone or with HCTZ in the treatment of hypertension and prevention of cardiovascular and renal complications.Link between the renin-angiotensin system and insulin resistance: implications for cardiovascular disease.Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment: a position paper of The Obesity Society and the American Society of Hypertension.Obesity-related hypertension: pathogenesis, cardiovascular risk, and treatment--a position paper of the The Obesity Society and The American Society of Hypertension.Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension.Prevention of type 2 diabetes; a systematic review and meta-analysis of different intervention strategies.Tissue-specific effects of valsartan on rstn and fiaf gene expression in the ob/ob mouse.A review of chemical therapies for treating diabetic hypertension.Lipid-lowering agents and new onset diabetes mellitus.Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.A 52-week prospective, cohort study of the effects of losartan with or without hydrochlorothiazide (HCTZ) in hypertensive patients with metabolic syndrome.Effect of moxonidine and amlodipine on serum YKL-40, plasma lipids and insulin sensitivity in insulin-resistant hypertensive patients-a randomized, crossover trial.ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.Does response of RAS blockade on serum K+ levels influence its glycemic-mitigating response when combined with hydrochlorothiazide?Ambulatory blood pressure adds to explaining benefits of AT-1 receptor blockade in the treatment of left ventricular hypertrophy.
P2860
Q28286410-7664F8D1-5550-4B01-A884-A304E4A07035Q28485173-1FD617E8-37FC-42BE-9E25-680724CF3FCDQ33552248-04BB1C5F-3680-4280-84EC-D64D5E28C631Q33561456-5F441672-DBB4-43EF-B274-145612C10B33Q33572259-85FDE9FD-4B09-41DB-9A64-1D5B7846F61CQ33689466-85D1FD68-9130-4FDE-B888-725BDF3A8154Q34012331-D69EB3F3-06C4-4DD5-9104-BBF71337B5DBQ34167806-DB4CC419-93FD-45FF-A072-422AC3FA2ED4Q34576535-55446996-C717-4E2B-A57C-22AB45540916Q34915602-080C902F-0D1C-40F8-B9EA-8EF38D062DF1Q34916263-4AF86133-5A47-4127-A063-2E752B3A1B2EQ35856525-4A554830-2D1F-4711-8AA3-AE8FF9BF6AE8Q36292056-C48302D4-F0F3-49FA-A50D-A7C9F6143EBBQ36432174-225B5DD8-832F-4184-A967-E8EAB8FE441EQ36815965-6CF11CC9-81D4-4910-9580-064AAF3FD4B0Q37117608-56A7970F-029B-4D84-9D97-C8D2902E29ADQ37150747-D8D2D7E9-439E-4449-8780-43F08B5A3DC9Q37202131-DAE9D54C-05A9-46F6-94C8-59045C3B1042Q37312565-42E4F73A-F335-4321-9234-E75194CC8FC1Q37362687-F89662D9-1F20-4122-BAAB-12B4447CDC28Q37427247-BA7AD9F7-8011-43B4-85F5-0F5BBE721273Q37492556-B2903D80-1E85-4451-8D28-CF4DAA00D5EDQ37798714-447D83EF-C2C2-458C-8283-DC74F7E6BE99Q37995862-DF4E3024-D0F3-4EF8-82EC-660C89CAE161Q38027785-5751170F-21F9-4BBB-AF4C-76154C8FC87FQ38032314-830B724F-E1EC-494D-B3DF-1B6674C57227Q38048843-FFD248E3-8DAA-4061-817E-1C99BD9FF4EAQ38071133-D9170381-D8BD-41BC-8240-1D6BF9A796B1Q38080812-9DDDDFFE-C6DE-4188-A561-DF880F9B9ED8Q38092017-616057AA-93A8-4158-B1F5-6AF08F941D09Q38183131-89987420-386C-4CD8-B34D-9DC3982485D1Q38343977-A1D68EE4-E485-4018-8D0D-3B805D62D94DQ39290260-4CB2BFB7-4485-47AE-BF05-8706CAAA997EQ43058605-A9CB9DE8-7B23-4E2C-B6BA-0B5D74403BC0Q43105414-D897FA34-FB09-4071-B583-A2FEB4D24A57Q43165906-B5C25C0A-2456-4502-B44F-9E219341E063Q43169808-2C01D662-A50C-4D3A-8D90-0A02278CC121Q45223569-55BA5FE5-937F-4ECC-8FD8-D5CCEAC7E709Q46828782-5E860D79-6708-405F-8BAC-C11BFC95F726Q46866935-8BBD342D-A513-4D91-ACD5-C0B0C059346C
P2860
Effects of valsartan compared to amlodipine on preventing type 2 diabetes in high-risk hypertensive patients: the VALUE trial.
description
2006 nĆ® lÅ«n-bĆ»n
@nan
2006 Õ©ÕøÖÕ”ÕÆÕ”Õ¶Õ« Õ
ÕøÖÕ¬Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕøÖÕ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ ÕµÖ
Õ¤ÕøÖÕ”Õ®
@hyw
2006 Õ©Õ¾Õ”ÕÆÕ”Õ¶Õ« Õ°ÕøÖÕ¬Õ«Õ½Õ«Õ¶ Õ°ÖÕ”ÕæÕ”ÖÕ”ÕÆÕ¾Õ”Õ® Õ£Õ«ÕæÕ”ÕÆÕ”Õ¶ Õ°ÕøÕ¤Õ¾Õ”Õ®
@hy
2006幓ć®č«ę
@ja
2006幓č«ę
@yue
2006幓č«ę
@zh-hant
2006幓č«ę
@zh-hk
2006幓č«ę
@zh-mo
2006幓č«ę
@zh-tw
2006幓č®ŗę
@wuu
name
Effects of valsartan compared ...... ive patients: the VALUE trial.
@ast
Effects of valsartan compared ...... ive patients: the VALUE trial.
@en
Effects of valsartan compared ...... ive patients: the VALUE trial.
@nl
type
label
Effects of valsartan compared ...... ive patients: the VALUE trial.
@ast
Effects of valsartan compared ...... ive patients: the VALUE trial.
@en
Effects of valsartan compared ...... ive patients: the VALUE trial.
@nl
prefLabel
Effects of valsartan compared ...... ive patients: the VALUE trial.
@ast
Effects of valsartan compared ...... ive patients: the VALUE trial.
@en
Effects of valsartan compared ...... ive patients: the VALUE trial.
@nl
P2093
P50
P1476
Effects of valsartan compared ...... sive patients: the VALUE trial
@en
P2093
Antonio Coca
Giuseppe Mancia
Gordon T McInnes
Jiri WidimskĆ½
Kenneth Jamerson
M Anthony Schork
Michael A Weber
Pierre Larochelle
Reuven Viskoper
Roland E Schmieder
P304
P356
10.1097/01.HJH.0000234122.55895.5B
P577
2006-07-01T00:00:00Z